[1]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658-662.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
　WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(7):658-662.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
点击复制

基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年7期
页码:
658-662
栏目:
出版日期:
2021-07-25

文章信息/Info

Title:
Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging
作者:
武志刚 孙佳莉 王巍
(哈尔滨医科大学附属第一医院磁共振室,黑龙江 哈尔滨 150001)
Author(s):
WU Zhigang; SUN Jiali; WANG Wei
(Department of Magnetic Resonance,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,Heilongjiang,China)
关键词:
肥厚型心肌病; 左室舒张功能; 心脏磁共振;  心肌延迟强化
Keywords:
Hypertrophic cardiomyopathy; Left ventricular diastolic function;  Cardiac magnetic resonance imaging ;  Late gadolinium enhancement
DOI:
10.16806/j.cnki.issn.1004-3934.2021.07.020
摘要:
目的 应用心脏磁共振成像（CMR）探索左室心肌延迟强化百分数（LGE%）与舒张功能是否存在相关性，并为临床预测及早期诊断肥厚型心肌病（HCM）患者是否存在舒张功能障碍提供依据。方法 回顾性分析在本院接受3.0 T CMR检查并确诊为非梗阻性肥厚型心肌病的患者65例及健康对照组45例，记录左室LGE%及代表左室舒张功能的左室早期峰值充盈率（ePFR）值，采用Mann-Whitney U检验比较HCM组与对照组ePFR，且将LGE%、基底段-延迟增强百分数（B-LGE%）、中段-延迟增强百分数（M-LGE%）、心尖段-延迟增强百分数(A-LGE%)与ePFR进行Spearman相关性分析，所有患者左室射血分数（LVEF）＞50%。 结果 HCM组患者与对照组ePFR差异具有统计学意义（P＜0.001），LGE%与ePFR呈负相关（r=-0.594，P=0.027），B-LGE%与ePFR呈中度负相关（r=-0.492，P =0.003），M-LGE%、A-LGE%与ePFR无相关性（r =-0.347，P=0.80(0.800??)；r=-0.459，P=0.21）。结论 B-LGE%及LGE%与ePFR呈负相关，且B-LGE%与ePFR相关性最为紧密，提示HCM患者左室基底段存在心肌纤维化时更易发生左室舒张功能降低，对于临床的治疗方案具有重要意义。
Abstract:
Objective To explore whether there is a correlation between left ventricular late gadolinium enhancement percentage(LGE%) and diastolic function by c ardiac magnetic resonance imaging(CMR),and provide evidence for clinical prediction and early diagnosis of diastolic dysfunction in patients with hypertrophic cardiomyopathy (HCM). 65 patients with nonobstructive hypertrophic cardiomyopathy who underwent 3.0 T CMR examination in The First Affiliated Hospital of Harbin Medical University and 45 healthy controls were retrospectively analyzed, and LGE% and early peak filling rate(ePFR) were recorded. Mann Whitney U test was used to compare ePFR between HCM group and control group. Spearman correlation analysis was performed between LGE%, basal segment-late gadolinium enhancement percentage(B-LGE%), mid-segment-late gadolinium enhancement percentage(M-LGE%),apical segment-late gadolinium enhancement percentage(A-LGE%) and ePFR,and left ventricular ejection fraction(LVEF) of all patients was more than 50%. Results The difference in ePFR between the HCM group and the control group was statistically significant (P＜0.001),LGE% was negatively correlated with ePFR (r =－0.594, P=0.027), B-LGE% was moderately negatively correlated with ePFR (r=－0.492, P=0.003),and M-LGE% and A-LGE% have no correlation with ePFR ( r=－0.347,P=0.80;r=－0.459,P=0.21). Conclusion B-LGE% and LGE% are negatively correlated with ePFR,and B-LGE% is more closely correlated with ePFR. This indicates that when there is myocardial fibrosis in the basal segment of left ventricle in HCM patients,the left ventricular diastolic function is more likely to decrease. This finding is of great significance for clinical treatment programs

参考文献/References:

[1].Wu CW,Wu R,Shi RY,et al. Histogram analysis of native T1?mapping and its relationship to left ventricular late gadolinium enhancement,hypertrophy,and segmental myocardial mechanics in patients with hypertrophic cardiomyopathy[J]. J ?Magn Reson Imaging,2019,49(3):668-677.
[2].Efthimiadis GK,Giannakoulas G,Parcharidou DG,et al. Clinical significance of tissue Doppler imaging in patients with hypertrophic cardiomyopathy[J]. Circ J,2007,71(6):897-903.
[3].徐敏,孙兆男,王旭超,等. 伴或不伴房颤的肥厚型心肌病患者左心结构与功能
[4].差异的MRI研究[J]. 磁共振成像 ,2019,10(11):821-825.
[5].Nagueh SF,Appleton CP,Gillebert TC,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography[J]. J Am Soc Echocardiogr,2009,22(2):107-133.
[6].杨钰粒,赵铭哲,于瀛,等. 肥厚型心肌病患者左心室纤维化特点及延迟钆增强
[7].心脏磁共振的临床应用现状[J]. 南京医科大学学报 (自然科学版),2019,39(11):1676-1680.
[8].Ji L,Hu W,Yong Y,et al. Left ventricular energy loss and wall shear stress assessed by vector flow mapping in patients with hypertrophic cardiomyopathy[J].?Int J Cardiovasc Imaging,2018,34(9):1383-1391.
[9].Avegliano G,Politi MT,Costabel JP,et al. Differences in the extent of fibrosis in obstructive and nonobstructive hypertrophic cardiomyopathy[J].J Cardiovasc Med (Hagerstown) ,2019,20(6):389-396.
[10].Todiere G,Aquaro GD,Piaggi P,et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2012,60(10):922-929.
[11].Moravsky G,Ofek E,Rakowski H,et al. Myocardial fibrosis in hypertrophic cardiomyopathy:accurate reflection of histopathological findings by CMR[J]. JACC Cardiovasc Imaging,2013,6(5):587-596.
[12].Varnava AM,Elliott PM,Sharma S,et al. Hypertrophic cardiomyopathy:the interrelation of disarray,fibrosis,and small vessel disease[J]. Heart,2000,84(5):476-482.
[13].Reindl M,Tiller C,Holzknecht M,et al. Global longitudinal strain by feature tracking for optimized prediction of adverse remodeling after ST-elevation myocardial infarction[J].?Clin Res Cardiol,2021,110(1):61-71.
[14].Rickers C,Wilke NM,Jerosch-Herold M,et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy [J].?Circulation,2005,112(6):855-861.
[15].Lorenzini M,Norrish G,Field E,et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers[J]. J Am Coll Cardiol,2020,76(5):550-559.
[16].Weng Z,Yao J,Chan RH,et al. Prognostic value of LGE-CMR in HCM: a meta-analysis[J]. JACC Cardiovasc Imaging ,2016,9(12):1392-1402.
[17].Flett AS,Hasleton J,Cook C,et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance[J]. JACC Cardiovasc Imaging,2011,4(2):150-156.
[18].王月,武柏林. 射血分数保留的心力衰竭左心室舒张功能的影像学评价 [J]. 国际医学放射学杂志 ,2019,42(1):66-70.
[19].Mendoza DD,Codella NC,Wang Y. Impact of diastolic dysfunction severity on global left ventricular volumetric filling—assessment by automated segmentation of routine cine cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2010,12(1):46.
[20].Bonow RO,Frederick TM,Bacharach SL,et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy:effect of verapamil[J]. Am J Cardiol, 1983,51(8):1386-1391 .
[21].Kawaji K,Codella NC,Prince MR,et al. Automated segmentation of routine clinical cardiac magnetic resonance imaging for assessment of left ventricular diastolic dysfunction[J].?Circ Cardiovasc Imaging,2009,2(6):476-484.
[22].Chen YZ,Qiao SB,Hu FH,et al. Left ventricular remodeling and fibrosis:sex differences and relationship with diastolic function in hypertrophic cardiomyopathy[J].?Eur J Radiol,2015,84(8):1487-1492.
[23].Nakamura T,Iwanaga Y,Yasuda M,et al. Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy:insights from cardiac magnetic resonance analysis[J].?Int J Cardiovasc Imaging,2016,32(4):613-620.

相似文献/References:

[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
　FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(7):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
　HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]吴仰帆 赖玉琼 王晓洲 蓝宁辉.组织多普勒成像联合Tei指数对原发性醛固酮增多症患者左心室舒张功能评估的相关性研究[J].心血管病学进展,2020,(2):214.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.029]
　WU Yangfan LAI Yuqiong WANG Xiaozhou LAN Ninghui.Study on the Correlation Between Tissue Doppler Imaging and Tei Index in Evaluating Left Ventricular Diastolic Function in Patients with Primary Aldosteronism[J].Advances in Cardiovascular Diseases,2020,(7):214.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.029]
[4]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
　MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(7):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[5]洪璐 曹明强 周亚峰.2016年ASE/EACVI指南评估的左室舒张功能对阵发性心房颤动术后复发的预测价值[J].心血管病学进展,2021,(5):464.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.019]
　HONG Lu,CAO Mingqiang,ZHOU Yafeng.Predictive Value of Left Ventricular Diastolic Function Assessed by 2016 ASE/EACVI Guidelines for Postoperative Recurrence of Paroxysmal Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(7):464.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.019]
[6]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
　DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(7):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[7]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
　SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[8]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
　WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[9]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(7):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[10]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
　LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(7):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]

更新日期/Last Update: 2021-09-10